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A Comparative Analysis of Major Clinical Outcomes with Drug-Eluting Stents
versus Bare Metal Stents in Male versus Female Patients
Ran Kornowski, Hana Vaknin-Assa, Abid Assali, Eli I Lev, Danny Dvir, Avital Porter,
Alexander Battler, Tamir Bental
Rabin Medical Center, Petah-Tikva, Israel
Background: The impact of different types of stents on clinical outcomes is of great
interest because coronary disease is a major cause of morbidity and mortality for both
genders. This study aimed to conduct a risk-adjusted gender-based analysis of clinical
outcomes following drug-eluting stent (DES) versus bare metal stent (BMS)
implantation in patients with coronary artery disease.
Methods: We compared risk-adjusted total mortality rate, myocardial infarction, and
event-free survival in a consecutive cohort of 7,662 patients undergoing percutaneous
coronary intervention at our institution, including 1835 (25.4%) women. Follow-up
was 6 months to 6.2 years (mean 3.5 years, median 3.6 years).
Results: Women were older than men and more likely to suffer from diabetes,
hypertension, or congestive heart failure. Smokers were more often men, and men were
more likely to have had prior coronary bypass surgery compared to women. A DES
was used in 39.9% of males and 39.5% of females. Both genders derived a significant
long-term clinical benefit from DESs compared to BMSs; advantages were observed
for mortality (men: HR=0.78, 95% CI: 0.64 - 0.96, p=0.016; women: HR=0.62, 95%
CI: 0.45 - 0.85, p=0.003) and major adverse cardiac events (men: HR=0.73, 95% CI:
0.63-0.84, p<0.001; women: HR=0.76, 95% CI: 0.52-0.84, p=0.001). Among BMS-
treated patients, women had worse cumulative clinical outcomes than men. DESs
eliminated the gender differences in cardiac prognosis.
Conclusion: Our analysis indicated a profound prognostic advantage for DESs versus
BMSs among both genders, though female patients appeared to derive the greatest
benefit.
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The Nine-Month Outcomes of a Polymer-Free Drug-Eluting Stent (YUKON)
Compared with Different Polymer Based Drug-Eluting Stents in Real-World
Coronary Artery Lesions
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Spitali Zemres, Prishtina, Albania
Background: We compared the safety and efficacy of different permanent polymer
based drug-eluting stents (PBS) with a polymer-free drug-eluting stent (PFS-Yukon).
In unselected real-world patients with coronary lesions of various complexities, we
retrospectively compared both stent designs.
Methods: A total of 617 lesions in patients with symptomatic CAD were treated with
PBS (n = 383) or with PFS (n = 234). The PBS group consisted of 44(12%) Cypher,
101(26%) Xience, 107(28%) Endeavor, 55(14%) Infinium and 75(20%) Coroflex
Please stents, assigned to patients and lesions by shelf disposal and target vessel
dimensions. The primary clinical endpoint of this study was a composite of cardiac
death, myocardial infarction and clinical-indicated target vessel revascularisation
(MACE).
Results: Follow-up was obtained in 98,2% of patients. All patients were treated with
clopidrogrel and aspirin during follow up. Polymer free stents were non-inferior to
polymer- stents for the primary endpoint at 9 months (13 [5.6%] vs 21 [5.5%], HR:
0.98 [95% CI 0.48-2.01], p for superiority=0.96). Frequency of cardiac death (5 [2.1%]
vs 6 [1.6%], p for superiority=0.41), myocardial infarction (4 [1.7%] vs 16 [4.2%],
p=0.07), and clinically-indicated target vessel revascularisation (8 [3.4%] vs 18 [4.7%],
p=0.29) were similar for both stent types. Analysis of MACE after 9 months resulted
in 4 (1.7%) definitive stent thrombosis causing MI in PFS vs. 18(4.7%) in PBS treated
lesions, with borderline significant difference (log rank, p=0.052). In the cox
proportional regression analysis of MACE, none of the stents showed different survival
according to stratification by presence of Diabetes, ST-elevationMI, multivessel
disease, Left anterior, long or small vessel lesions, (p=0.93; p=0.97; p=0.99; p=0.95;
p=0.96; p=0.85), respectively.
Conclusion: Up to 9 months after PCI of real-world coronary lesions, there were no
statistically significant differences in MACE between lesions treated with the polymer-
free YUKON stent and the group of polymer-based stents.
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Chromium Everolimus-Eluting Stent
Ruogu Li, Adrian F Low, Chi Hang Lee, Mark Chan, Swee Guan Teo, Koo Hui
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cardiac, National University Heart Centre, Singapore, Singapore
Background: The safety and efficacy of the first generation cobalt chromium
everolimus-eluting stent (EES) have been demonstrated in several trials. The PROMUS
Element (Boston Scientific, Natick, Massachusetts) stent is a new generation EES,
made of platinum chromium alloy with thin strut designed to improve radial strength,
radiopacity, vessel conformability, fracture resistance, side-branch access and
deliverability. We aim to compare the safety and efficacy of this novel PtCr-EES with
the first generation cobalt chromium EES (CoCr-EES) in patients who received them.
Methods: We analyzed retrospectively 805 patients who received PtCr-EES(n=391)
or CoCr-EES (n=414) from our centre cardiovascular database. The primary endpoint
was the 6-month composite major adverse cardiac events (MACE) that include cardiac
death, myocardial infarction, target vessel revascularization and stent thrombosis.
Results: The mean age of the cohort was 58.7±10.1 years with males constituting
82.7%. Diabetes mellitus was present in 322 (40.0%) patients. The majority (63.1%)
of the lesions treated were of AHA/ACC Type B2/C. The mean lesion length in the 2
groups were 26.14±12.19 mm (PtCr-EES) vs 24.14±11.86 (CoCr-EES), p=0.009
respectively; and the stent length were 31.27±14.38mm (PtCr-EES) vs 31.23±14.61mm
(CoCr-EES), p=0.96 respectively. At 6 months, the results were as follow:
Clinical Outcome
Conclusion: Our study showed that PtCr-EES stent, when used in real-world
population, showed similar medium-term efficacy as the first generation EES with no
safety concerns related to the novel stent material and design. The TVR rate is low at
<2% for both groups.
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Background: Despite the success of percutaneous intervention along with stent
deployment in opening up an occluded coronary artery in AMI patients, the
phenomenon of distal embolization may result in impaired myocardial perfusion and
myocardial recovery and remains a significant concern in reperfusion therapy. The
MGUARDTM stent (InspireMD, Tel Aviv, Israel) comprises a mesh which is wrapped
around a balloon-expandable, bare metal stent. The mesh is designed to trap thrombus
and fragile plaque against the vessel wall and prevent them from entering the lumen
thereby preventing distal embolization. The IMOS (International MGUARD
Observational Study) Registry enrolled consecutive patients treated with the
MGUARDTM stent with the objective to evaluate its clinical performance and safety.
Methods: The IMOS registry is a prospective, non-randomized, single arm,
multinational, observational study designed to enroll 1000 patients. Angiographic
exclusion criteria include heavily calcified lesions and large side branches. The primary
endpoint is MACE at 6 months. Patients are evaluated at 1, 6 and 12 months.
Results: A total of 382 patients who matched the inclusion/exclusion criteria have been
enrolled to date, and were sorted into groups according to clinical presentation and
number and type of stent deployed. A group of 203 patients (53.0% of patients enrolled
in the registry), who presented with STEMI and in whom only MGUARDTM was
implanted, were analyzed and are presented here. 43.6% of these patients suffered from
hyperlipidemia, 59.4% from hypertension and 15.3% from diabetes. 8.0% had prior
PCI and 9.9% had previous MI. The culprit lesion was in the RCA in 49.7% of cases
and in the LAD in 36.2%. A visible thrombus was seen in 98.0%. In 41%, thrombus
aspiration was used. Procedure success was 98.0% and final TIMI3 flow was achieved
in 93.5% of patients. At 30 days, 6 months and 1 year, MACE rates were 2.4%, 3.2%
and 6.0% respectively.
Conclusion: PCI with MGUARDTM represents an efficient and safe approach in
treating STEMI patients, with low rates of MACE and high rates of procedure and
angiographic success.
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Late Clinical Impact of Postprocedural Incomplete Stent Apposition and Late
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Background: There has been limited data regarding the late clinical impact of post-
procedural incomplete stent apposition (PISA) and late incomplete stent apposition
(LISA) in the newer generation of drug eluting stent. The aim of this study was to
investigate the incidence of LISA and change of PISA during follow up.
Methods: We prospectively enrolled 101 patients who underwent percutaneous
coronary intervention (PCI) in de novo coronary lesions; stable angina (n=26), unstable
angina (n=61), and non-ST segment elevation myocardial infarction (n=13) (62.2±8.8
years, 72 male, 121 lesions). The group was randomly assigned (proportion of 2:1) to
zotarolimus eluting stent (group I, n=81, Endeavor Resolute, Medtronic, MN) or
everolimus eluting stent (group II, n=40, Xience V, Abbott Vascular, Illinois). Post-
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